Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 10.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 10.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.760
Low
5.00
Averages
10.50
High
14.00
Current: 5.760
Low
5.00
Averages
10.50
High
14.00
Goldman Sachs
Salveen Richter
Early-Stage Biotech -> Buy
upgrade
$11
2025-12-04
Reason
Goldman Sachs
Salveen Richter
Price Target
$11
2025-12-04
upgrade
Early-Stage Biotech -> Buy
Reason
Goldman Sachs analyst Salveen Richter moved its rating on Taysha Gene Therapies to Buy with an $11 price target from Early-Stage Biotech designation. The firm is positive on the company's outlook in Rett syndrome. believe Taysha can achieve the response rate of 33% needed to meet the minimum threshold for success in the REVEAL study, the analyst tells investors in a research note.
Cantor Fitzgerald
Kristen Kluska
upgrade
$13 -> $19
2025-11-21
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$13 -> $19
2025-11-21
upgrade
Reason
Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Taysha Gene Therapies to $19 from $13 and keeps an Overweight rating on the shares.
Citizens JMP
Outperform
maintain
$6 -> $8
2025-11-05
Reason
Citizens JMP
Price Target
$6 -> $8
2025-11-05
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Taysha Gene Therapies to $8 from $6 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported Q3 results and provided a safety update on 12 dosed patients and a finalized statistical analysis plan that is achievable based on available data, the analyst tells investors in a research note. Finalized REVEAL plans have weathered the regulatory storm, and Citizens believes the protocol is currently the best approach in Rett, giving Taysha a significant competitive advantage.
Raymond James
Strong Buy
initiated
$13
2025-10-20
Reason
Raymond James
Price Target
$13
2025-10-20
initiated
Strong Buy
Reason
Raymond James initiated coverage of Taysha Gene Therapies with a Strong Buy rating and $13 price target. Based on "strong results" from Part A of the Phase 1/2 REVEAL trial and "constructive" feedback from FDA, the firm views Taysha as well-positioned for success in its pivotal trial for patients with Rett syndrome, the analyst tells investors. There are currently no approved therapies addressing the root genetic cause of Rett syndrome, which the firm sees giving Taysha "a clear path to success," the analyst added.
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
